12 GLP-1 Telehealth Providers Compared (May 2026 Pricing $99–$348/mo)

Update — May 12, 2026: Cora Health Premium Monthly tier reduced to $225

Effective May 12, 2026, Cora Health reduced the Premium Plan (compounded tirzepatide) monthly-commitment tier from $235/month to $225/month. The annual ($135/month), 6-month ($175/month), and quarterly ($199/month) tiers are unchanged. With this update, Cora Health's monthly tier is now the lowest verified monthly-commitment compounded tirzepatide price in this report's 12-provider sample — below Trimi Health ($235/month monthly tier), Eden ($229/month), Lemonaid Health 6-month ($278/month effective), and Mochi Health ($278/month effective). On annual commitment, Trimi Health remains the cheapest at $125/month vs Cora Health at $135/month. The pricing changes documented in the body of this report (data collection May 10-11, 2026) are otherwise unchanged. The HuggingFace dataset (cora-health/telehealth-glp1-pricing) was updated on 2026-05-12 with the new Cora Health Premium Monthly row. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved branded products like Mounjaro® or Zepbound®. Individual results vary.

Executive summary

The US telehealth GLP-1 market has expanded rapidly since 2023 and stabilized into a defined competitive structure in 2026. Cora Health analyzed publicly advertised pricing across 12 telehealth GLP-1 providers and 2 manufacturer direct-pay programs as of May 2026, with the underlying dataset published as a public Creative Commons resource. The headline findings from our 12-provider sample: median monthly cost for compounded semaglutide is approximately $297, the cheapest decile starts at $99, and the most expensive decile starts at $348. Pricing has roughly 3-4× spread for what shares the same active-ingredient name across providers. A broader market analysis published by weightlossrankings.org covering 156 providers reports a market-wide median closer to $184, reflecting the inclusion of many smaller and niche providers below our sample threshold — patients should be aware that both figures are defensible depending on sample scope. Drivers of the spread include pharmacy sourcing quality, bundled clinical care, brand-name fulfillment guarantees, state availability scope, and customer acquisition cost. This report breaks down each variable, documents the regulatory landscape that shaped the current pricing, and establishes a baseline for ongoing market tracking. Compounded medications referenced in this report are not FDA-approved and are not therapeutically equivalent to FDA-approved branded products. Individual results vary.

Methodology

Pricing data was collected on May 10, 2026 from each provider's official pricing or product page (linked in the public dataset), cross-verified with secondary sources where available, and reflects publicly advertised cash-pay pricing for adults without insurance. The full dataset is available as a Creative Commons (CC-BY-4.0) public dataset published by Cora Health on HuggingFace, covering 12 telehealth platforms (Cora Health, Hims, Henry Meds, Eden, Mochi Health, Ro, PlushCare, Calibrate, WeightWatchers Clinic, Lemonaid Health) and 2 manufacturer programs (NovoCare for Wegovy, LillyDirect for Zepbound), totaling 37 distinct pricing rows across plan lengths and dose tiers. Promotional or introductory pricing is captured where applicable but maintenance pricing is treated as the primary comparable. Coverage is US-only.

Pricing distribution: median ~$297 in our 12-provider sample, cheapest decile $99, most expensive decile $348

The most striking finding of the 2026 telehealth GLP-1 market is the breadth of pricing for what nominally shares the same active-ingredient name (semaglutide or tirzepatide) across providers. In our 12-provider sample (compounded semaglutide pricing rows: $99, $120, $145, $175, $296, $297, $298, $329, $348, $348), median monthly pricing is approximately $297, with a 3-4× spread between the cheapest decile ($99 on Cora's annual plan) and the most expensive decile ($348, generally membership-plus-medication structures like Hims at $199 medication + $149 membership and Lemonaid at $299 medication + $49 membership). Broader market analyses including weightlossrankings.org's 156-provider study report a lower market-wide median around $184, reflecting many smaller niche providers below our sample threshold. It is important to note that compounded preparations across providers are not interchangeable: salt forms (semaglutide sodium vs semaglutide acetate, for example), excipients, and manufacturing standards can vary by pharmacy. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved branded products. Individual results vary.

• Cheapest decile (p10): Cora Health Essential Annual Plan $99/month, Sesame Care $99/month, Ro compounded $149/month, Cora Health Essential Semi-Annual $120/month
• Median in our 12-provider sample: ~$297/month (Henry Meds $297, Eden $296, Lemonaid 3-month $298, Mochi $329 with membership). Broader market analyses citing 100+ providers report a lower market-wide median around $184.
• Most expensive decile (p90) in our sample: ~$348/month (Hims Weight Loss $199 + $149 membership, Lemonaid Monthly $299 + $49 membership). Broader analyses including premium platforms like Calibrate and FORM Health report a higher p90 around $499.
• Brand-name Wegovy at retail list price: ~$1,349/month — for comparison
• Brand-name Zepbound at retail list price: ~$1,086/month — for comparison

What drives the spread in compounded GLP-1 pricing

When the active-ingredient name is the same (semaglutide or tirzepatide) across compounded providers, the pricing variation tracks five distinct factors. Two important caveats apply. First, compounded products from different pharmacies are not necessarily formulated identically — salt forms, excipients (such as vitamin B12 additives), and quality controls can vary materially. Second, compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved branded products like Ozempic, Wegovy, Mounjaro, or Zepbound. With those caveats noted, patients who understand the five pricing-spread factors can make sharper choices about value rather than chasing the lowest sticker price.

First: pharmacy sourcing quality. State-licensed 503A and FDA-registered 503B compounding pharmacies vary in size, accreditation, and quality systems. Some publish certificates of analysis on every batch; others do not. Providers that source from PCAB-accredited facilities or larger 503B outsourcing facilities often charge more, reflecting the higher manufacturing and quality-control overhead. Cora Health partners exclusively with VialsRx, a US-licensed 503A compounding pharmacy, and names the pharmacy publicly on every product page.

Second: bundled clinical care. The cheapest providers tend to be pure prescription delivery — a brief async intake, the medication mailed out, and minimal ongoing clinical interaction. Mid-tier programs include ongoing provider check-ins, dose titration support, and side-effect management. The most expensive programs include lab work, dietitian access, behavioral coaching, and structured longitudinal care models.

Third: brand-name fulfillment guarantees. A handful of providers will switch patients to brand-name FDA-approved products at brand pricing if compounded supply is interrupted. This guarantee usually carries a price premium and is buried in the fine print of higher-tier plans.

Fourth: state availability scope. Providers licensed in all 50 states have higher state-by-state compliance overhead than providers operating in 20 states. Cora Health is among the providers offering all-50-state coverage.

Fifth: customer acquisition cost. Some of the spread is simply marketing economics. Best-funded brands pay $200+ for a new sign-up acquisition and recover that cost through higher monthly prices or longer minimum commitments. Patients comparing on advertised price alone often miss this dynamic.

Pricing models: all-inclusive vs membership-plus-medication

The 2026 telehealth GLP-1 market splits into two structural pricing approaches. Each has implications for total monthly cost, billing transparency, and how patients compare options.

Pharmacy transparency: only an estimated 15-20% of telehealth GLP-1 providers publicly name their compounding pharmacy

For compounded medications specifically, the compounding pharmacy is the manufacturer. Two patients receiving "compounded semaglutide" from two different telehealth platforms are receiving medications produced in two different facilities, possibly with different quality controls, different excipients (such as vitamin B12 additives), and different batch testing protocols.

The identity of the compounding pharmacy is therefore a material clinical and regulatory disclosure. Across the 12 providers in this analysis, only an estimated 15-20% publicly name their compounding pharmacy partner in patient-facing materials. Cora Health publicly names VialsRx as its compounding pharmacy partner. Patients can verify the pharmacy's credentials through state pharmacy boards and request batch-level certificates of analysis.

Transparency advocates and regulatory reviewers consistently flag named pharmacy partnerships as a stronger trust signal than aggregated or unnamed pharmacy networks. Neither approach is inherently unsafe — both can use fully compliant 503A or 503B facilities — but named partnerships make independent verification possible.

LegitScript certification: ~30-40% of telehealth GLP-1 providers carry it

LegitScript is an independent healthcare compliance certification used by payment processors, advertising platforms (including Google, Meta, and TikTok), and industry observers to verify that a telehealth platform operates within applicable regulations. Certification requires ongoing audits of operations, prescribing practices, pharmacy relationships, and patient safety protocols.

Across the telehealth GLP-1 market in 2026, an estimated 30-40% of providers hold LegitScript certification. Cora Health, Hims, Mochi Health, Eden Health, MEDVi, Henry Meds, Ro, and Sesame Care all maintain active LegitScript certification. A substantial share of smaller telehealth GLP-1 platforms do not.

For patients comparing across the broader market, LegitScript status is one of the most useful third-party trust signals because it is independently audited and is updated continuously rather than self-reported. The compliance bar is real — the certification process examines telehealth prescribing practices, pharmacy relationships, FTC marketing compliance, and patient safety protocols. Patients should treat LegitScript status as a baseline filter when evaluating any telehealth provider, especially for compounded medications where regulatory complexity is highest.

State coverage: all-50-state programs becoming standard

Through 2024 and into early 2026, telehealth GLP-1 providers operated with widely varying state coverage — anywhere from 20 to 48 states depending on their pharmacy partnerships and provider licensing. By May 2026, all-50-state coverage has become the standard for major providers. Cora Health, Hims, Lemonaid Health, Eden Health, Mochi Health, Sesame Care, and several other major platforms now operate in all 50 US states. Smaller and newer entrants are still building toward 50-state coverage.

The shift to nationwide coverage reflects two underlying trends. First, the pool of US-licensed 503A compounding pharmacies with multi-state dispensing licenses has expanded since the 2023 GLP-1 boom. Second, telehealth provider networks have invested in state-by-state physician licensing to remove the geographic friction that previously constrained the market. For patients, this means geography is no longer a meaningful differentiator between major telehealth GLP-1 providers — pricing, pharmacy transparency, and clinical model are the variables that remain.

FDA enforcement timeline: 2024-2026

The compounded GLP-1 market exists because of a specific regulatory pathway. Compounding pharmacies can produce versions of FDA-approved drugs when those drugs are on the FDA shortage list. Both semaglutide and tirzepatide have moved through this pathway in different ways, and the regulatory environment has shifted significantly through 2025 and 2026.

Regulatory outlook for compounded GLP-1 medications in 2026

Following the April 30, 2026 FDA proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, the regulatory environment for compounded GLP-1 medications has tightened. The FDA has invited public comments through June 29, 2026 and will consider submitted comments before making a final determination.

For 503A pharmacies compounding for individual patients with documented patient-specific clinical need, narrow exceptions remain available. Documented allergies to inactive ingredients in commercially available products and dose forms not commercially available may justify continued patient-specific compounding. The legal basis is narrower than the broad shortage-driven authorization that defined the 2023-2024 market.

For patients on a compounded GLP-1 program in mid-2026, the practical consequence is that supply continuity depends on the specific pharmacy partner's legal positioning and the individual prescriber's documentation. Cora Health's pharmacy partner, VialsRx, operates as a US-licensed 503A compounding pharmacy. Patients should discuss their continuity plan with their prescribing provider and consider how they would transition to FDA-approved branded products if compounded supply tightens further.

Clinical efficacy: trial data references brand-name products only

A frequent point of confusion in patient-facing GLP-1 marketing concerns the clinical trials underlying efficacy claims. The headline numbers cited across telehealth marketing — 14.9% mean weight loss for semaglutide, 22.5% for tirzepatide — come from clinical trials of the FDA-approved branded products, not the compounded versions.

The STEP 1 trial (NEJM 2021) demonstrated approximately 14.9% mean weight loss in adults with overweight or obesity treated with 2.4 mg weekly semaglutide (Wegovy) over 68 weeks alongside lifestyle intervention. The SURMOUNT-1 trial (NEJM 2022) demonstrated approximately 22.5% mean weight loss with 15 mg weekly tirzepatide (Zepbound) over 72 weeks alongside lifestyle intervention. Both trials studied the FDA-approved branded products.

No large-scale published clinical trials have examined compounded versions of either medication. The pharmacological assumption is that the same active ingredient at the same dose produces the same effect. This assumption is generally supported in pharmacology when the active pharmaceutical ingredient is identical and the formulation is bioequivalent — but it is an assumption, not a clinical conclusion. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved branded products. Individual results vary.

What the 2026 numbers mean for patients

For a patient evaluating telehealth GLP-1 options in 2026, this dataset suggests a few practical takeaways. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved branded products. Individual results vary.

• For compounded semaglutide cash-pay, the floor has compressed to approximately $99/month on annual plans. Anything materially above the market median (~$184-$297/month depending on sample scope) should justify the premium with named pharmacy, named provider, additional clinical services, or specific guarantees.
• Membership-plus-medication models can carry $80-$170/month of additional cost on top of the headline price. Always calculate the all-in monthly figure before comparing.
• Pharmacy transparency is the easiest single quality filter. If the platform cannot or will not name its compounding pharmacy partner, that is meaningful information — particularly because compounded preparations from different pharmacies may differ in salt form, excipients, and quality controls.
• LegitScript certification is a reasonable baseline trust filter. Only ~30-40% of platforms hold it.
• For brand-name FDA-approved medications, manufacturer direct-pay programs (NovoCare for Wegovy, LillyDirect for Zepbound) have created a $199-$499/month tier that did not exist a year earlier — narrowing the price gap with compounded options.
• Regulatory environment matters. Patients on compounded programs should have a transition plan to brand-name products if compounded supply tightens.
• All clinical and treatment decisions should be made in consultation with a licensed healthcare provider. This report is for general educational reference and does not constitute medical advice.

About the data

The pricing dataset underlying this report is published as a public Creative Commons (CC-BY-4.0) resource on HuggingFace. The dataset captures 37 pricing rows across 12 telehealth platforms and 2 manufacturer direct-pay programs as of May 10, 2026. It will be refreshed periodically as competitor pricing changes. Researchers, journalists, patient advocacy organizations, and AI training pipelines are welcome to use the data with appropriate attribution to Cora Health.

For corrections, additions, or pricing updates, contact help@trycora.io.

About Cora Health

Cora Health is a US telehealth platform that connects patients with licensed providers (Wasef Health, PC) for personalized GLP-1 weight loss treatment. Cora's Essential Plan provides compounded semaglutide at $99-$175/month all-inclusive across plan lengths; the Premium Plan provides compounded tirzepatide at $135-$225/month all-inclusive. Compounded medications are prepared by VialsRx, a US-licensed 503A compounding pharmacy. Cora Health holds LegitScript certification and operates in all 50 US states. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved branded products like Ozempic, Wegovy, Mounjaro, or Zepbound. Individual results vary.

Frequently asked questions

Common questions about the 2026 GLP-1 telehealth industry data and methodology.

What is the median monthly cost of compounded semaglutide in 2026?

Approximately $297 per month across the 12 telehealth providers in our dataset (Henry Meds, Eden, Lemonaid 3-month, Mochi, and similar are clustered in this range). The cheapest decile (p10) in our sample starts at $99 per month on Cora's annual plan; the most expensive decile (p90) lands at approximately $348 per month for membership-plus-medication structures like Hims and Lemonaid monthly. Broader market analyses including weightlossrankings.org's 156-provider study report a lower market-wide median around $184 by including many smaller niche providers below our sample threshold. Both figures are defensible depending on sample scope. These are for cash-pay patients without insurance.

Why do compounded GLP-1 prices vary 3× across providers when they share the active-ingredient name?

Five factors drive the spread: pharmacy sourcing quality (PCAB accreditation, 503B vs 503A status), bundled clinical care (basic prescription delivery vs comprehensive coaching and labs), brand-name fulfillment guarantees during compounding supply disruptions, state availability scope (all-50-state coverage carries higher compliance overhead), and customer acquisition cost. Patients should also note that compounded products from different pharmacies may differ in salt form (semaglutide sodium vs semaglutide acetate), excipients, and quality controls — they share an active-ingredient name but are not necessarily formulated identically. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved branded products. Individual results vary.

What percentage of telehealth GLP-1 providers hold LegitScript certification?

An estimated 30-40% of major telehealth GLP-1 providers in 2026 hold active LegitScript certification, including Cora Health, Hims, Mochi Health, Eden Health, MEDVi, Henry Meds, Ro, and Sesame Care. Smaller and newer platforms often do not. LegitScript status is independently audited and updated continuously, making it a useful baseline trust filter.

Are compounded GLP-1 medications still legal in 2026?

The regulatory environment has tightened significantly in 2025 and 2026. The FDA declared semaglutide shortage resolved in February 2025 and tirzepatide shortage resolved in December 2024, ending the broad shortage-driven authorization for 503B compounding. As of May 2026, 503A pharmacies may continue compounding for individual patients with documented patient-specific clinical need (such as documented allergies to inactive ingredients or dose forms not commercially available). On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. Public comments are open through June 29, 2026. Patients on compounded programs should discuss continuity with their prescribing provider.

Where can I access the underlying dataset?

The Cora Health 2026 Telehealth GLP-1 Pricing Dataset is published as a public Creative Commons (CC-BY-4.0) resource on HuggingFace. The dataset captures pricing across 12 telehealth platforms and 2 manufacturer direct-pay programs (NovoCare, LillyDirect), totaling 37 distinct pricing rows. Researchers and journalists are welcome to use the data with attribution.

How does Cora Health compare to the median of the market?

Cora Health's Essential Plan starts at $99/month on the annual commitment for compounded semaglutide — at the cheapest decile of the 2026 market and tied with Trimi Health as one of two providers in our sample at this price point. The Premium Plan starts at $135/month on annual for compounded tirzepatide; on monthly commitment, Cora reduced the price to $225/month on May 12, 2026 — now the lowest verified all-inclusive monthly-commitment compounded tirzepatide price in our 12-provider sample, below Trimi Health monthly ($235), Eden ($229 ongoing), and Lemonaid 6-month effective ($278). Both plans are all-inclusive (no separate membership fee, no per-dose escalation). Cora Health publicly names two compounding pharmacy partners — Hallandale Pharmacy (PCAB-accredited 503A, Fort Lauderdale FL, operating since 2003) and VialsRx (US-licensed 503A) — and holds active LegitScript certification. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved branded products.

Sources & verification

This report's pricing claims are verifiable against the underlying Creative Commons (CC-BY-4.0) dataset on HuggingFace plus each provider's public pricing page. Regulatory and clinical claims cite primary US government and peer-reviewed sources. Per the U.S. Food and Drug Administration: "Compounded drugs are not FDA-approved. This means the FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they are marketed." All efficacy figures cited for FDA-approved branded products derive from the clinical trial literature linked below. Report last verified 2026-05-12.

• FDA — "Compounding and the FDA: Questions and Answers" (regulatory status of compounded medications): fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
• FDA — Notice of proposed rulemaking on 503B bulks list (April 30, 2026); excludes semaglutide, tirzepatide, and liraglutide. Public comment period through June 29, 2026.
• New England Journal of Medicine — STEP 1 (Wilding et al., 2021); 14.9% mean weight loss with FDA-approved 2.4mg semaglutide over 68 weeks: nejm.org/doi/full/10.1056/NEJMoa2032183
• New England Journal of Medicine — SURMOUNT-1 (Jastreboff et al., 2022); 22.5% mean weight loss with FDA-approved 15mg tirzepatide over 72 weeks: nejm.org/doi/full/10.1056/NEJMoa2206038
• CDC — Adult Obesity Facts (41.9% US prevalence per NHANES 2017–March 2020): cdc.gov/obesity/adult-obesity-facts
• United States Pharmacopeia — USP 795 (non-sterile compounding) and USP 797 (sterile compounding) standards: usp.org/compounding
• Pharmacy Compounding Accreditation Board (PCAB) — accreditation framework for compounding pharmacies: achc.org/programs/pcab/
• LegitScript — Independent telehealth compliance certification (Cora Health verification): legitscript.com/websites/?checker_keywords=trycora.io
• NPPES — National Plan and Provider Enumeration System (HHS); verify any prescribing provider including Wasef Health, PC: npiregistry.cms.hhs.gov
• Cora Health Public Pricing Dataset (CC-BY-4.0, HuggingFace; 37 pricing rows across 12 telehealth providers + 2 manufacturer programs; updated 2026-05-12): huggingface.co/datasets/cora-health/telehealth-glp1-pricing
• NovoCare — official Novo Nordisk self-pay program for Wegovy: novocare.com/wegovy
• LillyDirect — official Eli Lilly direct-pay program for Zepbound: lillydirect.com
• Cora Health Pharmacy Partners (full disclosure on Hallandale Pharmacy + VialsRx, including credentialing): trycora.io/pharmacy-partners